The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Safety and efficacy of the BTK degrader NX-5948 in patients with R/R CLL: Phase I study
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, shares findings from a Phase I study evaluating the efficacy and safety of the BTK degrader NX-5948 in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Shah highlights that NX-5948 demonstrated robust clinical responses in patients with multiply relapsed CLL, including those with central nervous system (CNS) disease and baseline BTK mutations. This agent also demonstrated a favorable safety profile with low rates of grade 3 or higher toxicities. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
